-
1
-
-
0030015821
-
Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants
-
Van der Meer F.J., Rosendaal F.R., Vandenbroucke J.P., and Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 76 (1996) 12-16
-
(1996)
Thromb Haemost
, vol.76
, pp. 12-16
-
-
Van der Meer, F.J.1
Rosendaal, F.R.2
Vandenbroucke, J.P.3
Briet, E.4
-
2
-
-
0029072271
-
Optimal oral anticoagulant therapy in patients with mechanical heart valves
-
Cannegieter S.C., Rosendaal F.R., Wintzen A.R., et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 333 (1995) 11-17
-
(1995)
N Engl J Med.
, vol.333
, pp. 11-17
-
-
Cannegieter, S.C.1
Rosendaal, F.R.2
Wintzen, A.R.3
-
3
-
-
15844427401
-
Bleeding complications of oral anticoagulant treatment: An inceptioncohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy
-
Palareti G., Leali N., Coccheri S., et al. Bleeding complications of oral anticoagulant treatment: An inceptioncohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348 (1996) 423-428
-
(1996)
Lancet
, vol.348
, pp. 423-428
-
-
Palareti, G.1
Leali, N.2
Coccheri, S.3
-
4
-
-
0031729679
-
Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
-
Hirsh J., Dalen J.E., Anderson D.R., et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114 Suppl 5 (1998) 445S-469S
-
(1998)
Chest
, vol.114
, Issue.SUPPL. 5
-
-
Hirsh, J.1
Dalen, J.E.2
Anderson, D.R.3
-
5
-
-
0027257511
-
Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
-
Landefeld C.S., and Beyth R.J. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med. 95 (1993) 315-328
-
(1993)
Am J Med.
, vol.95
, pp. 315-328
-
-
Landefeld, C.S.1
Beyth, R.J.2
-
7
-
-
0027268465
-
Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: A clinical practice proposal
-
Sorano G.G., Biondi G., Conti M., et al. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: A clinical practice proposal. Haemostasis 23 (1993) 77-82
-
(1993)
Haemostasis
, vol.23
, pp. 77-82
-
-
Sorano, G.G.1
Biondi, G.2
Conti, M.3
-
8
-
-
0031722693
-
Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin
-
Panneerselvam S., Baglin C., Lefort W., and Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol. 103 (1998) 422-424
-
(1998)
Br J Haematol.
, vol.103
, pp. 422-424
-
-
Panneerselvam, S.1
Baglin, C.2
Lefort, W.3
Baglin, T.4
-
9
-
-
0023039327
-
Stereoselective interaction between the R enantiomer of warfarin and cimetidine
-
Choonara I.A., Cholerton S., Haynes B.P., et al. Stereoselective interaction between the R enantiomer of warfarin and cimetidine. Br J Clin Pharmacol. 21 (1986) 271-277
-
(1986)
Br J Clin Pharmacol.
, vol.21
, pp. 271-277
-
-
Choonara, I.A.1
Cholerton, S.2
Haynes, B.P.3
-
10
-
-
0031015345
-
Human P450 metabolism of warfarin
-
Kaminsky L.S., and Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacol Ther. 73 (1997) 67-74
-
(1997)
Pharmacol Ther.
, vol.73
, pp. 67-74
-
-
Kaminsky, L.S.1
Zhang, Z.Y.2
-
11
-
-
0030700392
-
Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers
-
Yamazaki H., and Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem Pharmacol. 54 (1997) 1195-1203
-
(1997)
Biochem Pharmacol.
, vol.54
, pp. 1195-1203
-
-
Yamazaki, H.1
Shimada, T.2
-
12
-
-
0031807762
-
Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
-
Takahashi H., Kashima T., Nomizo Y., et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther. 63 (1998) 519-528
-
(1998)
Clin Pharmacol Ther.
, vol.63
, pp. 519-528
-
-
Takahashi, H.1
Kashima, T.2
Nomizo, Y.3
-
13
-
-
0029798351
-
Genetic analysis of the human cytochrome P450 CYP2C9 locus
-
Stubbins M.J., Harries L.W., Smith G., et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6 (1996) 429-439
-
(1996)
Pharmacogenetics
, vol.6
, pp. 429-439
-
-
Stubbins, M.J.1
Harries, L.W.2
Smith, G.3
-
14
-
-
0029658591
-
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
-
Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6 (1996) 341-349
-
(1996)
Pharmacogenetics
, vol.6
, pp. 341-349
-
-
Sullivan-Klose, T.H.1
Ghanayem, B.I.2
Bell, D.A.3
-
16
-
-
0036914221
-
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
-
Scordo M.G., Pengo V., Spina E., et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharm Ther. 72 (2002) 702-710
-
(2002)
Clin Pharm Ther.
, vol.72
, pp. 702-710
-
-
Scordo, M.G.1
Pengo, V.2
Spina, E.3
-
17
-
-
0034785607
-
Phenytoin metabolic ratio: A putative marker of CYP2C9 activity in vivo
-
Caraco Y., Muszkat M., and Wood A.J. Phenytoin metabolic ratio: A putative marker of CYP2C9 activity in vivo. Pharmacogenetics 11 (2001) 587-596
-
(2001)
Pharmacogenetics
, vol.11
, pp. 587-596
-
-
Caraco, Y.1
Muszkat, M.2
Wood, A.J.3
-
18
-
-
0033608466
-
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
-
Aithal G.P., Day C.P., Kesteven P.J., and Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (1999) 717-719
-
(1999)
Lancet
, vol.353
, pp. 717-719
-
-
Aithal, G.P.1
Day, C.P.2
Kesteven, P.J.3
Daly, A.K.4
-
19
-
-
0033884635
-
Cytochrome P450 polymorphisms are associated with reduced warfarin dose
-
Freeman B.D., Zehnbauer B.A., McGrath S., et al. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 128 (2000) 281-285
-
(2000)
Surgery
, vol.128
, pp. 281-285
-
-
Freeman, B.D.1
Zehnbauer, B.A.2
McGrath, S.3
-
20
-
-
0034283762
-
Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivi ty and risk of over-anticoagulation in patients on long-term treatment
-
Taube J., Halsall D., and Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivi ty and risk of over-anticoagulation in patients on long-term treatment. Blood 96 (2000) 1816-1819
-
(2000)
Blood
, vol.96
, pp. 1816-1819
-
-
Taube, J.1
Halsall, D.2
Baglin, T.3
-
21
-
-
17944366735
-
Interindividual variability in sensitivity to warfarin-nature or nurture?
-
Loebstein R., Yonath H., Peleg D., et al. Interindividual variability in sensitivity to warfarin-nature or nurture?. Clin Pharmacol Ther. 70 (2001) 159-164
-
(2001)
Clin Pharmacol Ther.
, vol.70
, pp. 159-164
-
-
Loebstein, R.1
Yonath, H.2
Peleg, D.3
-
22
-
-
1542346414
-
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin
-
Kamali F., Khan T.I., King B.P., et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 75 (2004) 204-212
-
(2004)
Clin Pharmacol Ther.
, vol.75
, pp. 204-212
-
-
Kamali, F.1
Khan, T.I.2
King, B.P.3
-
23
-
-
0033694203
-
Genetic modulation of oral anticoagulation with warfarin
-
Margaglione M., Colaizzo D., D'Andrea G., et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 84 (2000) 775-778
-
(2000)
Thromb Haemost
, vol.84
, pp. 775-778
-
-
Margaglione, M.1
Colaizzo, D.2
D'Andrea, G.3
-
24
-
-
0037012465
-
Association between CYP2C9 genetic variants and anti coagulation-related outcomes during warfarin therapy
-
Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anti coagulation-related outcomes during warfarin therapy. JAMA 287 (2002) 1690-1698
-
(2002)
JAMA
, vol.287
, pp. 1690-1698
-
-
Higashi, M.K.1
Veenstra, D.L.2
Kondo, L.M.3
-
25
-
-
0042915883
-
Warfarin dose adjustments based on CYP2C9 genetic polymor phisms
-
Linder M.W., Looney S., Adams III J.E., et al. Warfarin dose adjustments based on CYP2C9 genetic polymor phisms. J Thromb Thrombolysis 14 (2002) 227-232
-
(2002)
J Thromb Thrombolysis
, vol.14
, pp. 227-232
-
-
Linder, M.W.1
Looney, S.2
Adams III, J.E.3
-
26
-
-
0016916438
-
Prediction of creatinine clearance from serum creatinine
-
Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
-
(1976)
Nephron
, vol.16
, pp. 31-41
-
-
Cockcroft, D.W.1
Gault, M.H.2
-
27
-
-
4644230820
-
The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
-
(Suppl)
-
(Suppl). Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 204-233
-
(2004)
Chest
, vol.126
, pp. 204-233
-
-
Ansell, J.1
Hirsh, J.2
Poller, L.3
-
28
-
-
0030826062
-
Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationaryphase liquid chromatography with ultraviolet or fluorescence and online circular dichroism detection
-
Takahashi H., Kashima T., Kimura S., et al. Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationaryphase liquid chromatography with ultraviolet or fluorescence and online circular dichroism detection. J Chromatogr B Biomed Sci Appl. 701 (1997) 1-80
-
(1997)
J Chromatogr B Biomed Sci Appl.
, vol.701
, pp. 1-80
-
-
Takahashi, H.1
Kashima, T.2
Kimura, S.3
-
29
-
-
0032511212
-
Chiral phase analysis of warfarm enantiomers in patient plas ma in relation to CYP2C9 genotype
-
Herne K.R., Gaedigk A., Gupta G., et al. Chiral phase analysis of warfarm enantiomers in patient plas ma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl. 710 (1998) 143-148
-
(1998)
J Chromatogr B Biomed Sci Appl.
, vol.710
, pp. 143-148
-
-
Herne, K.R.1
Gaedigk, A.2
Gupta, G.3
-
30
-
-
0004211855
-
-
W.W. Norton & Co, New York, NY
-
Freedman D., Pisani R., Purves R., et al. Statistics. 2nd ed (1991), W.W. Norton & Co, New York, NY
-
(1991)
Statistics. 2nd ed
-
-
Freedman, D.1
Pisani, R.2
Purves, R.3
-
31
-
-
0036008657
-
Audit of anticoagulant therapy and acute hospital admissions
-
Hirri H.M., and Green P.J. Audit of anticoagulant therapy and acute hospital admissions. Clin Lab Haematol 24 (2002) 43-45
-
(2002)
Clin Lab Haematol
, vol.24
, pp. 43-45
-
-
Hirri, H.M.1
Green, P.J.2
-
32
-
-
0242417135
-
Genetic and environmental risk factors for oral anticoagulant over dose
-
Verstuyft C., Robert A., Morin S., et al. Genetic and environmental risk factors for oral anticoagulant over dose. Eur J Clin Pharmacol. 58 (2003) 739-745
-
(2003)
Eur J Clin Pharmacol.
, vol.58
, pp. 739-745
-
-
Verstuyft, C.1
Robert, A.2
Morin, S.3
-
34
-
-
0033918935
-
The influence of (R)and (S)-warfarin, vitamin K and vi tamin Kepoxide upon warfarin anticoagulation
-
Kamali F., Edwards C., Butler T.J., and Wynne H.A. The influence of (R)and (S)-warfarin, vitamin K and vi tamin Kepoxide upon warfarin anticoagulation. Thromb Haemost 84 (2000) 39-42
-
(2000)
Thromb Haemost
, vol.84
, pp. 39-42
-
-
Kamali, F.1
Edwards, C.2
Butler, T.J.3
Wynne, H.A.4
-
35
-
-
0029123928
-
The influence of age, liver size and enantiomer concentrations on warfarin requirements
-
Wynne H., Cope L., Kelly P., et al. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol. 40 (1995) 203-207
-
(1995)
Br J Clin Pharmacol.
, vol.40
, pp. 203-207
-
-
Wynne, H.1
Cope, L.2
Kelly, P.3
-
36
-
-
0031783832
-
In vivo age-related changes in hepatic drug-oxidizing capacity in humans
-
Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 23 (1998) 247-255
-
(1998)
J Clin Pharm Ther.
, vol.23
, pp. 247-255
-
-
Tanaka, E.1
-
37
-
-
0035909047
-
Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin
-
Hylek E.M., Regan S., Go A.S., et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 135 (2001) 393-400
-
(2001)
Ann Intern Med.
, vol.135
, pp. 393-400
-
-
Hylek, E.M.1
Regan, S.2
Go, A.S.3
-
38
-
-
0031898907
-
The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis
-
Le Couteur D.G., and McLean A.J. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 34 (1998) 359-373
-
(1998)
Clin Pharmacokinet
, vol.34
, pp. 359-373
-
-
Le Couteur, D.G.1
McLean, A.J.2
-
39
-
-
33645679794
-
The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose
-
Herman D., Locatelli I., Grabnar I., et al. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol. 62 (2006) 291-296
-
(2006)
Eur J Clin Pharmacol.
, vol.62
, pp. 291-296
-
-
Herman, D.1
Locatelli, I.2
Grabnar, I.3
-
40
-
-
0023276451
-
Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans
-
O'Reilly R.A., Trager W.F., Rettie A.E., and Goulart D.A. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther. 42 (1987) 290-294
-
(1987)
Clin Pharmacol Ther.
, vol.42
, pp. 290-294
-
-
O'Reilly, R.A.1
Trager, W.F.2
Rettie, A.E.3
Goulart, D.A.4
-
41
-
-
0024330636
-
The incidence and clinical significance of amiodarone and acenocoumarol interaction
-
Caraco Y., and Chajek-Shaul T. The incidence and clinical significance of amiodarone and acenocoumarol interaction. Thromb Haemost 62 (1989) 906-908
-
(1989)
Thromb Haemost
, vol.62
, pp. 906-908
-
-
Caraco, Y.1
Chajek-Shaul, T.2
-
43
-
-
21144448879
-
Effect of VKORC1 haplotypes on transcriptional regulation and warfarm dose
-
Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarm dose. N Engl J Med. 352 (2005) 2285-2293
-
(2005)
N Engl J Med.
, vol.352
, pp. 2285-2293
-
-
Rieder, M.J.1
Reiner, A.P.2
Gage, B.F.3
-
44
-
-
11244332058
-
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarm
-
D'Andrea G., D'Ambrosio R.L., Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarm. Blood. 105 (2005) 645-649
-
(2005)
Blood.
, vol.105
, pp. 645-649
-
-
D'Andrea, G.1
D'Ambrosio, R.L.2
Di Perna, P.3
-
45
-
-
1642335299
-
Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarm sensitivity
-
Shikata E., Ieiri I., Ishiguro S., et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarm sensitivity. Blood 103 (2004) 2630-2635
-
(2004)
Blood
, vol.103
, pp. 2630-2635
-
-
Shikata, E.1
Ieiri, I.2
Ishiguro, S.3
-
46
-
-
19144371313
-
Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9
-
Loebstein R., Vecsler M., Kurnik D., et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther. 77 (2005) 365-372
-
(2005)
Clin Pharmacol Ther.
, vol.77
, pp. 365-372
-
-
Loebstein, R.1
Vecsler, M.2
Kurnik, D.3
|